A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 fresh embryo transfer cycles

Trial Profile

A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 fresh embryo transfer cycles

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Nolasiban (Primary)
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPLANT2
  • Sponsors ObsEva
  • Most Recent Events

    • 12 Oct 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2018.
    • 06 Sep 2017 According to an ObsEva media release, more than 1000 patients have been recruited and the company anticipates randomization of at least 760 patients in this trial. Initial results are anticipated in the first quarter of 2018.
    • 06 Sep 2017 Status changed from recruiting to active, no longer recruiting, as reported in an ObsEva media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top